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Abstract 
Early-onset bipolar disorder has significant morbidity and mortality. Development of safe, effective 
treatments to which patients will adhere is critical. Pharmacologic interventions for childhood bipolar 
spectrum disorders are limited and are associated with significant risk for adverse events. Diet and nutrition 
research suggests vitamins, minerals, and other nutrients are important underpinnings of general physical 
and mental health; furthermore, they may even be useful in treating mood dysregulation by providing a 
more favorable risk–benefit ratio than contemporary psychotropic agents. This article reviews the literature 
on multinutrient supplementation and mental health, and examines a case study of a 12-year-old boy with 
bipolar disorder and co-morbid diagnoses treated for 6 years with conventional medication and finally a 
multinutrient supplement. The multinutrient supplement in this case study is EMPowerplus (EMP+), a 36-
ingredient supplement containing 16 minerals, 14 vitamins, 3 amino acids, and 3 antioxidants. It was used 
to treat a 12-year-old boy initially diagnosed with bipolar disorder not otherwise specified (BP-NOS) at age 
6, and whose diagnosis evolved by age 10 to bipolar I (BP-I), mixed, with psychotic features. He also met 
criteria for generalized anxiety disorder by age 8 and obsessive-compulsive disorder by age 10. After 6 
years of conventional treatment (ages 6–12), he received 14 months of EMP+. Symptom manifestation over 
7 years is described in conjunction with treatment history.EMP+ resulted in outcome superior to 
conventional treatment. This report adds to accumulating preliminary evidence that further basic science 
and clinical studies of multinutrient supplements are warranted. 
Introduction 
Childhood-onset bipolar spectrum disorders (BPSD; bipolar I [BP-I], bipolar II [BP-II], 
Bipolar not otherwise specified [BP-NOS], and cyclothymia) represent a significant public health 
concern (McClellan et al. 2006; Brown et al. 2008). Although recent clinical trials have found 
efficacy in using atypical antipsychotics for BP-I, treatment literature is lacking for children with 
BP-II, BP-NOS, and cyclothymia, despite the functional impairment inherent to these diagnoses 
(Kowatch et al. 2009). Medications recommended in current treatment guidelines (Kowatch et al. 
2005; McClellan et al. 2006) appear beneficial but carry significant risk for adverse events. 
In a recent retrospective study of medical and pharmacy claims from a cohort of 4140 
youths prescribed one of five types of atypical or two conventional antipsychotics compared to a 
random sample of 4500 youth not treated with psychotropics, the treated cohort had higher rates 
of a variety of metabolic and cardiovascular side effects (McIntyre and Jerrell 2008). These 
adverse events included higher risk of obesity, type 2 diabetes mellitus, cardiovascular 
conditions, dyslipidemia, and orthostatic hypotension. Researchers found metabolic and 
cardiovascular risks increased for youths taking multiple antipsychotics (McIntyre and Jerrell 
2008). 
In another study monitoring side effects of atypical neuroleptics, including clozapine, 
olanzapine, and risperidone, all three drugs caused drowsiness and hypoactivity. A total of 30–
60% of children and adolescents taking clozapine experienced constipation, increased salivation, 
orthostatic hypotension, and nasal congestion. These side effects were seen in patients taking 
olanzapine and risperidone less often, but 5–15% of participants taking olanzapine or risperidone 
suffered from rigidity, tremor, and dystonia. Participants in all three atypical neuroleptic 
conditions gained weight during the study, but those in the olanzapine group gained significantly 
more weight than those in the other two treatment groups (4.6 ± 1.9 kg; Fleischhaker et al. 2006). 
Recent clinical trials of depression and bipolar disorders in youth show approximately 
20–25% of participants dropped out of psychotropic medication treatment (Biederman et al. 
2007; DelBello et al. 2007). DelBello and colleagues (2007) conducted a single-blind, 12-week 
study of quetiapine in adolescents aged 12–18 in which researchers observed a 25% drop out rate 
of adolescents whose diagnoses included dysthymia, BP-II, BP-NOS, major depressive disorder, 
or cyclothymia. Biederman and colleagues (2007) conducted an 8-week, open-label trial of 
aripiprazole in children aged 6–17 with BP in which they observed a 21% drop out rate. 
Additionally, a recent study of an anticonvulsant mood stabilizer in children failed to show any 
superiority to placebo (Wagner et al. 2006). 
Dietary supplementation and mental health 
Previous research on diet and nutrition suggests multinutrient supplements may have a 
beneficial effect on mood with limited side effects, which might provide a primary treatment 
with a more favorable risk–benefit ratio for some youth suffering from BPSD than currently 
available pharmacologic interventions (Kaplan et al. 2001; Popper 2001; Kaplan et al. 2002; 
Kaplan et al. 2004; Kaplan et al. 2007). Increasing evidence suggests that nutrition affects the 
structure and functioning of the brain due to the high percentage of human metabolic activity 
accounted for by this organ. In adulthood, the brain accounts for 20% of the human basal 
metabolic rate; as a neonate, this number is as high as 44% (Benton 2008). Nutritional 
interventions, particularly multi-ingredient multinutrient supplements, have several possible 
mechanisms of action to explain a hypothesized association with clinical improvement in mood. 
These are summarized below. Preliminary studies have been conducted with the multinutrient 
supplement EMPowerPlus (EMP+) (Truehope Nutritional Support Ltd., Raymond, Alberta, 
Canada). This supplement consists of 16 minerals, 14 vitamins, 3 amino acids, and 3 antioxidants 
(a full list of ingredients can be found on the manufacturer’s website at 
http://www.truehope.com). Relevant literature is discussed below. 
Individual vitamins and minerals. 
The neuropsychiatric effects of certain frank nutritional deficiencies are well known: e.g., 
thiamine/B1 (Wernicke encephalopathy), niacin/B3 (pellagra), cyanocobalamin/B12 (psychosis 
of pernicious anemia), and iodine (myxedema madness). Milder effects of more subtle 
deficiencies are increasingly recognized, possibly related either to genetic variations in which 
some patients may be more vulnerable or to historical changes in diet composition. Nutritional 
supplements have been related to a wide range of human health factors from neuronal 
development to depression (Hibbeln 1998; Noaghiul and Hibbeln 2003). Specific nutrients 
linked to mental health include iron, copper, zinc, vitamins B1, B6, B12, D, E, and folate (Kaplan 
et al. 2007). 
Multinutrient combinations. 
Recently, interest has turned to combinations of nutritional deficiencies, because there is 
plausible reasoning to support the concept that if one nutrient is deficient, a grouping of nutrients 
are deficient, and the level of one nutrient can affect the adequacy of others (Benton 2008; 
Kaplan et al. 2007). Kaplan and colleagues (2007) review studies of vitamins and minerals and 
their relationship with mood symptoms, then present four conceptual frameworks that are 
compatible, can coexist, and may aid understanding of how nutrients may improve mood 
(Kaplan et al. 2007). First, they suggest mood dysregulation may result from innate metabolism 
malfunctions, ultimately affecting brain functioning; such innate mechanisms could involve 
inefficient use of nutrients. Second, they state mood instability may result from deficiencies in 
methylation of molecules responsible for completing DNA transcription, switching on genes, 
regulating protein generation, activating enzymes, and synthesizing neurotransmitters. Third, 
nutrition deficiencies may alter gene expression, leading to mood instability. Fourth, unstable 
mood may result from long-latency effects of nutrient deficiencies that alter brain development 
directly or by way of dysfunctional nutrient absorption. Although these four frameworks require 
considerable empirical evaluation, they provide possible mechanisms through which nutrient 
supplementation may affect mood symptoms (Kaplan et al. 2007). 
Gesch et al. (2002) examined the effects of vitamins, minerals, and essential fatty acids 
on antisocial behavior in a randomized, double-blind, placebo-controlled study of 231 adult 
prisoners. Participants spent, on average, 142 days on the recommended daily dose of two 
supplements (one capsule of Forceval, a vitamin-mineral supplement that contains 25 vitamins 
and minerals, and four capsules of Efamol Marine, an essential fatty acid supplement containing 
omega-6 and omega-3 essential fatty acids) or placebo (identically appearing oil-based gelatin 
capsules). The Efamol Marine dose contains 1260 mg of linoleic acid, 160 mg of gamma 
linolenic acid, 80 of eicosapentaenoic acid, and 44 mg of docosahexaenoic acid (Gesch et al. 
2002). 
Participants’ antisocial behavior was measured throughout the study period using 
disciplinary reports. Results revealed a decrease in overall antisocial behavior for participants 
taking nutritional supplements compared to placebo. Neither group reported notable side effects. 
Overall infringements resulting in disciplinary reports decreased by 35.1% in the active 
condition for participants who took the supplement for at least 2 weeks compared to placebo 
participants, whose disciplinary reports decreased by 6.7% (p < 0.001). Intent-to-treat analyses 
showed active condition participants experienced a 26% decrease in overall infringements 
resulting in disciplinary reports compared to placebo participants (p < 0.03). This research 
suggests a combination of vitamin–mineral supplements and essential fatty acids may decrease 
antisocial behavior; the researchers speculate that physiological changes caused by dietary 
intervention affect mental health and warrant further clinical investigation (Gesch et al. 2002). 
Schoenthaler and Bier (2000) examined the impact of low-dose vitamin–mineral tablets 
on rates of violent, antisocial behavior in 468 school children aged 6–12. Using a stratified 
randomized double-blind, placebo-controlled design, half the sample received daily vitamin–
mineral supplementation at 50% of the U.S. recommended daily allowance (RDA) for 4 months. 
The other half received placebo. Eighty children were disciplined at least once during the 
September 1 to May 1 study interval. The 40 who received supplementation had a 47% lower 
mean rating of antisocial behavior than the 40 on placebo (1 vs. 1.875 disciplinary actions). 
Children on supplementation had lower antisocial behavior ratings for every type of recorded 
infraction: Threats/fights, vandalism, disrespect, disorderly conduct, assault/battery, defiance, 
obscenities, refusal to work/serve, endangering others, and nonspecified offenses. 
EMP+ Multinutrient supplement. 
As indicated above, there is clear scientific rationale for studying multinutrient 
formulations. Early clinical findings suggest multinutrient supplements may have promising 
therapeutic effects in patients with BP (Kaplan et al. 2001; Kaplan et al. 2002; Simmons 2003). 
EMP+ is a commercially available product with the most extensive foundation of empirical 
support to date. Background research on this product, summarized below, suggests it is worthy 
of more rigorous scientific evaluation. 
Animal study. 
Halliwell and Kolb (2003) studied newborn rats who received frontal or posterior parietal 
lesions on day 3, then subsequently were fed either normal rat chow or rat chow enhanced with a 
rodent-appropriate dose of EMP+. At day 60, the supplemented animals exhibited reversal of 
behavioral deficits (e.g., performance on spatial learning tasks) and had significant regrowth of 
cortical tissue compared to unsupplemented rats. Behaviorally, the animals were significantly 
calmer than unsupplemented rats. 
Adult studies. 
Initial studies were conducted with adult patients resistant to conventional treatments. 
Open-label trials were first reported on adults diagnosed with BP (Kaplan et al. 2001). Kaplan 
and colleagues studied 11 patients aged 19–46 years for 6–21 months. The effects of EMP+ on 
symptoms of bipolar disorder were assessed using the Hamilton Depression Rating Scale (HAM-
D) (Hamilton 1960), the Young Mania Rating Scale (YMRS) (Young et al. 1978), and the Brief 
Psychiatric Rating Scale (BPRS) (Overall and Gorham 1962). Participants could continue using 
concurrent psychiatric medications under the supervision of their psychiatrist. Results indicated a 
55–66% reduction in symptoms reported on the HAM-D, YMRS, and BPRS as well as a 50% 
decrease in the need for psychotropic medications. Participants reported one mild side effect, 
infrequent/transitory nausea, which occurred most commonly when participants took their 
supplement without food (Kaplan et al. 2001). The researchers recommended further empirical 
investigation of EMP+ by other researchers. 
Simmons (2003) described his use of EMP+ in private clinical practice. He reported that 
12 out of 19 treatment-resistant adult patients diagnosed with BP-I (n = 14) and BP-II (n = 5) 
who began what is now an outdated version of EMP+ displayed marked improvement; 3 
appeared moderately improved and 1 person showed mild improvement after a mean of 5.3 
weeks on the supplement. Thirteen participants completely stopped taking their original 
psychiatric medications after an average of 5.2 weeks on EMP+ (range = 3–10 weeks) and 
remained stable. Side effects included mild gastrointestinal problems, but a majority of patients 
(11 of 19, 58%) continued using this supplement instead of their previously prescribed 
psychopharmacological medications (Simmons 2003). While placebo-controlled trials are 
currently being conducted by Kaplan and colleagues in adults, placebo-controlled trials have not 
yet commenced with children (Kaplan et al. 2001). However, several case series and open trial 
studies have been conducted, reviewed below. 
Child studies. 
Several studies examine the efficacy of EMP+ in children. In a naturalistic ABACB trial, 
Popper (2001) followed a 10-year-old boy diagnosed with BP who experienced severe temper 
tantrums multiple hours a day for 4 months in his clinical practice. After 2 days of taking EMP+ 
at full dose, the boy’s behavior improved significantly. Within 5 days, all tantrums and 
irritability ceased. After 14 days, EMP+ was discontinued. Within 2 days of discontinuation, 
tantrums began again. The boy was then put on a different supplement, which, according to 
parent and teacher reports, provided 60% of the benefit noted on EMP+. EMP+ was resumed a 
second time, resulting in resolution of the tantrums and irritability. In a follow-up study, Popper 
followed 22 more patients with BP in his clinical practice (2001). Participants included 10 adults, 
9 adolescents, and 3 preadolescents. Although mild side effects were common (e.g., headache), a 
majority of participants (19/22, 86%) responded positively. Furthermore, 11 of the 15 patients 
(73%) previously on psychotropics remained stable without resumption of these medications at 
6-month and 9-month follow-up assessments (Popper 2001). 
Kaplan and associates also conducted an open-label ABAB trial with 2 boys aged 8 and 
12 (Kaplan et al. 2002). These participants displayed irritability, mood lability, and explosive 
rage at baseline. The 8-year-old boy had diagnoses of atypical obsessive-compulsive disorder 
(OCD) and attention-deficit/hyperactivity disorder (ADHD). The 12-year-old boy was diagnosed 
with pervasive developmental disorder (PDD). The 8-year-old displayed consistent explosive 
rage, irritability, and obsessions with guns (but no compulsions) during baseline and each 
withdrawal phase. When on EMP+ these behaviors were almost completely eliminated. His 
obsessive thoughts ceased, the frequency and duration of his temper outbursts decreased 
significantly, and his mood fluctuations minimized. After more than 2 years of treatment, the boy 
remained well and free of side effects while taking 25% of his initial dose of EMP+. The second 
boy, 12 years old, displayed consistent irritability, negative attitude, temper outbursts, and 
extremely disruptive behavior in school at baseline. These behaviors subsided markedly while on 
EMP+. His mood impairment and temper levels returned to baseline status during treatment 
withdrawal. He demonstrated marked improvement in mood stabilization and behavior when 
treatment was reintroduced. Stimulant medication was still required in addition to EMP+ to 
control ADHD symptoms. After almost 3 years of treatment, this boy also maintained wellness 
without adverse side effects on 25% of his original dose (Kaplan et al. 2002). 
Kaplan and colleagues also completed a case series to further test the impact of EMP+ in 
11 children ages 8–15 (Kaplan et al. 2004). All had mood and/or behavioral problems. Diagnoses 
at intake included: BP (n = 3; 1 co-morbid with anxiety, 1 with behavior disorders); Asperger 
plus an anxiety disorder (n = 2); ADHD+ co-morbid anxiety and/or behavior disorders (n = 5); 
and Praeder–Willi syndrome, ODD+ anxiety (n = 1). Nine of the 11 (82%) completed the open-
label trial. Intent-to-treat analyses indicated significantly decreased scores on the Youth Outcome 
Questionnaire (YOQ) (p < 0.001) and YMRS (p < 0.01) from baseline to final visit. For the 9 
completers, improvement was significant on 7/8 (88%) Child Behavior Checklist scales, YOQ 
and YMRS (p < 0.05 to p < 0.001). The authors concluded that results from this study support 
the need for formal clinical trials of nutritional interventions in children with mood and 
behavioral dysregulation (Kaplan et al. 2004). 
It is important to note all above publications used a now-outdated version of EMP+, one 
that often caused gastrointestinal side effects. In the new version, the ingredients are processed 
differently; in particular, the minerals are pulverized so the individual particle size has been 
significantly reduced to as low as 14–15 microns. Consequently, the ingredients now look like 
powder and pack into fewer capsules. There have also been some small reductions in quantities 
of several vitamins (e.g., vitamin A). This updated version is the one used in the intervention 
described below. 
Case Presentation 
This case presentation follows the treatment of a 12-yearold boy (“John”) diagnosed with 
BP-NOS, which later developed into BP-I with psychotic features, generalized anxiety disorder 
(GAD), and OCD. Enuresis also emerged while taking lithium. By age 6, John experienced 
severe mood cycling, sadness, irritability, self-harming behaviors, sleep disturbance, and severe 
tantrums. He also experienced elevated mood, poor peer relations, low frustration tolerance, 
flight of ideas, aggressive behavior, hyperactivity, and impulsive negative behaviors. By age 8, 
John developed impairing anxiety and worsening mood symptom intensity and cycling, 
increased destructive behavior, transient suicidal ideation, and increased global impairment. 
These symptoms continued as he grew older, and between ages 10 and 11, John began 
experiencing auditory hallucinations, developed obsessions and compulsions, and displayed 
increasingly disrespectful and aggressive behaviors. He reported hearing intrusive, commanding 
voices when he became anxious, telling him to act on his obsessions and do things he did not 
want to do, and threatening him. At one point, John reported hearing voices almost 100 times in 
one week telling him, “If you don’t do this you’ll surely die.” and “Don’t listen to them 
[referring to parents and other adults],” When he was 10 years old, John specifically noted the 
voices told him he would die on the day John Glenn dies. John’s symptoms became so impairing 
he was removed from his private school and transferred to home schooling. 
John’s treatment team frequently altered his medications from the time he was 6 years old 
until he was 12 years old (2001–2007) in conjunction with individual/family psychoeducational 
psychotherapy (Fristad et al., in press ) provided by the second author (see Table 1). Medication 
changes were due to intolerable side effects and/or inadequate treatment response. During this 
time, he took various combinations of prescription and over-the-counter agents, including 
lithium citrate, risperidone, lithium carbonate, clonidine, flax seed, desmopressin, omega-3 fatty 
acids, magnesium, trazodone, gabapentin, valproic acid, propranolol, quetiapine, aripiprazole, 
lorazepam, and lamotrigine. No medication, alone or in combination, maintained a desirable 
mood balance or consistent improvement in global functioning over an extended period of time. 
When John was 12 years old, his mother approached his therapist (the second author) 
asking about EMP+. Coincidentally, the authors were intending to begin an open-label trial of 
EMP+ at their treatment center; however, there was a considerable delay in commencing the 
study due to impediments in receiving all research approvals needed. Thus, rather than wait, the 
family chose to work independently with the Truehope staff in starting EMP+ and received 
directions to taper psychotropic medication from his child and adolescent psychiatrist. The 
family continued to report John’s progress to his therapist over the subsequent 14 months. 
John’s transition from psychotropic medication to EMP+ is chronicled in Table 2. John 
took 5 capsules per day, then 10 per day, and then the recommended 15 capsules per day. After 7 
days on EMP+, he began to reduce his lithium carbonate and lamotrigine as recommended by the 
Truehope consultant and his psychiatrist. After 19 days on EMP+, John was completely off all 
psychotropic medications. 
Throughout this tapering-and-titration process, John experienced transient episodes of 
irritability, headache, dizziness, and fatigue. However, his global functioning notably increased. 
As treatment continued, John began interacting more appropriately with peers, remained calm 
and playful throughout most of the day, slept throughout the night, remained focused and 
efficient while completing schoolwork, and experienced decreased compulsions. Hallucinations 
ceased. John continued to experience brief periods in the afternoon when he would become 
frustrated, irritable, or defiant with his parents. However, his parents reported these behaviors 
were consistently followed by a sincere apology, which they viewed as an improvement 
compared to previous behavior. The night terrors and previously mentioned side effects ceased, 
his bowel movements normalized, his skin appeared smooth without dry patches, and his 
symptoms remained stable. His anxiety decreased, functioning was no longer impaired at home, 
with schoolwork, or with peers, and his impulsivity and fidgeting decreased substantially. All 
diagnoses fully remitted. 
Extended follow-up information 
After 4 months of EMP+, John’s mother increased his dose from 15 capsules a day to 18 
capsules to manage emerging irritability, possible mood cycling, and ‘‘odd’’ behavior. She 
reported this increase relieved his symptoms. One month later, the dose was returned to 15 
capsules of EMP+ daily. John has maintained health over the subsequent 9 months. He enrolled 
in regular public school for the first time, where he plays successfully on the school soccer and 
baseball teams and maintains friendships. His parents subjectively report that improvements in 
his functioning while taking EMP+ are greater than those he made in the past on other 
medications. His only additional interventions are drinking a half cup of whey protein mixed in 
milk in the morning during sports seasons while very active and using a lightbox during the 
winter. According to his mother, EMP+ helps keep him “clear, slowed down, peaceful, settled 
and happy.” 
Discussion 
Pharmacological intervention is considered to be the firstline treatment for children with 
BP, and recent reviews of the research suggest mood stabilizers or atypical antipsychotics should 
be the first psychotropics considered for children with BP-I (Kowatch, et al. 2009). 
Unfortunately, research on other psychotropic medications and varying presentations of pediatric 
bipolar disorder (BP-II, BP-NOS, cyclothymia) is limited, and those agents found efficacious are 
associated with risk for adverse events (Kowatch et al. 2005). It may take an average of 9 months 
to 2 years until an efficacious drug combination is found to stabilize mood in youths, and relapse 
rates are high (Kowatch et al. 2009). The Food and Drug Administration (FDA) recently 
approved the use of risperidone and aripiprizole in children with BP, although many children 
experience significant metabolic side effects on therapeutic doses (Slatko 2007). Lithium is 
another FDA-approved psychotropic medication for youths as young as 12 years, and it also is 
associated with numerous adverse side effects. Developing safe and effective treatments for 
early-onset BP to which patients will adhere is critical.
 
 
